Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Patients with end stage heart failure have significant symptoms (including fatigue and
shortness of breath) which prevent them from being able to perform most activities of daily
living. Milrinone is one of the inotropic medications that has been studied and used in the
treatment of end stage heart failure. End stage heart failure patients awaiting a heart
transplantation often have to be maintained on IV milrinone 24 hours a day through a chronic
IV line. Two problems arise with this therapy. First, the IV line itself creates an
opportunity for infection and blood clots, in addition to interfering with patient's quality
of life. Second, patients may be exposed to higher levels of milrinone when given IV than are
necessary for maintaining their heart's function.
By doing this study the investigators hope to learn if a new way of giving HF patients
milrinone can lower the levels of plasma milrinone which may lessen the chance of medication
side effects, while still preserving the beneficial effects of milrinone. Additionally if the
inhaled route of administration is effective patients may not need to have invasive IV lines
to administer the medication (currently standard practice) which can cause other unwanted
side effects.
Phase:
Phase 1
Details
Lead Sponsor:
University of Kansas Medical Center Vanderbilt University
Collaborators:
Lipscomb University Vanderbilt University Medical Center